静脉注射免疫球蛋白用于COVID-19相关中重度急性呼吸窘迫综合征患者(ICAR):多中心、双盲、安慰剂对照3期试验
ICAR试验为法国43个中心的多中心、双盲、安慰剂对照3期试验,纳入PCR确诊COVID-19、接受有创机械通气≤72小时且合并中重度ARDS的患者146例(IVIG组69例、安慰剂组77例),按1:1随机接受IVIG 2 g/kg分4天(每次0.5 g/kg、每次输注至少8小时)或等容积生理盐水(10 mL/kg)。主要终点第28天无通气天数在IVIG组为0.0天(IQR 0.0–8.0)、安慰剂组为0.0天(IQR 0.0–6.0),差值估计0.0(0.0–0.0),p=0.21,无统计学差异。严重不良事件IVIG组22例(32%)共78起、安慰剂组15例(20%)共47起,p=0.089,IVIG组有增多趋势但未达统计学显著。作者认为IVIG未改善第28天临床结局,其对COVID-19早期阶段的作用应在未来试验中评估。
要点
- 纳入标准为PCR确诊COVID-19、有创机械通气≤72小时且合并中重度ARDS,IVIG 2 g/kg分4天给药未改善第28天无通气天数(两组中位数均为0.0天,差值0.0[0.0–0.0],p=0.21)。
- 给药方案为IVIG 2 g/kg分4次、每次0.5 g/kg、每次输注至少8小时,于有创机械通气最初96小时内开始;安慰剂组给予等容积生理盐水10 mL/kg。
- 严重不良事件IVIG组22例(32%)共78起 vs 安慰剂组15例(20%)共47起(p=0.089),有增多趋势但未达统计学显著。
- 作者认为IVIG对COVID-19中重度ARDS第28天临床结局无改善,其对COVID-19早期阶段的作用应在未来试验中评估。
适用人群与场景
- 法国43个中心纳入的PCR确诊COVID-19、接受有创机械通气≤72小时并合并中重度ARDS的患者,共146例(女性43例[29%]),IVIG组69例(47%)、安慰剂组77例(53%)。
- 纳入时按中心及入组前有创机械通气时长分层(<12小时、12–24小时、>24–72小时)。
诊断标准与关键阈值
- PCR确诊COVID-19并合并中重度ARDS,接受有创机械通气≤72小时。
- 治疗须在有创机械通气最初96小时内开始。
处置流程与药物剂量
- IVIG组:IVIG 2 g/kg分4天给予,分为4次输注、每次0.5 g/kg,每次输注至少8小时。
- 安慰剂组:等容积生理盐水(0.9%氯化钠)10 mL/kg,于相同时段输注。
- 随机分组按中心及入组前有创机械通气时长(<12小时、12–24小时、>24–72小时)分层。
研究设计与关键结果
- 多中心、双盲、安慰剂对照3期试验,法国43个中心,2020年4月3日至10月20日随机146例(女性43例[29%]):IVIG组69例(47%)、安慰剂组77例(53%)。
- 主要终点第28天无通气天数(意向性治疗分析):IVIG组中位数0.0天(IQR 0.0–8.0)vs 安慰剂组0.0天(IQR 0.0–6.0),差值估计0.0(0.0–0.0),p=0.21。
- 严重不良事件:IVIG组22例(32%)共78起 vs 安慰剂组15例(20%)共47起,p=0.089。
证据类型、等级与局限
- 证据类型:多中心、双盲、安慰剂对照3期随机对照试验。
- 作者结论:IVIG未改善第28天临床结局,严重不良事件有增多趋势但未达统计学显著;IVIG对COVID-19早期阶段的作用应在未来试验中评估。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于COVID-19相关中重度ARDS且接受有创机械通气≤72小时的患者,本试验中IVIG 2 g/kg分4天给药未改善第28天无通气天数(差值0.0[0.0–0.0],p=0.21)。
- 本试验中IVIG组严重不良事件有增多趋势但未达统计学显著(22例[32%]vs 15例[20%],p=0.089)。
- 作者认为IVIG对COVID-19早期阶段的作用应在未来试验中评估。
指南或共识出处
- ICAR试验,注册号ClinicalTrials.gov NCT04350580,发表于Lancet Respiratory Medicine;资助:Programme Hospitalier de Recherche Clinique。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a major complication of COVID-19 and is associated with high mortality and morbidity. We aimed to assess whether intravenous immunoglobulins (IVIG) could improve outcomes by reducing inflammation-mediated lung injury.
METHODS: In this multicentre, double-blind, placebo-controlled trial, done at 43 centres in France, we randomly assigned patients (1:1) receiving invasive mechanical ventilation for up to 72 h with PCR confirmed COVID-19 and associated moderate-to-severe ARDS to receive either IVIG (2 g/kg over 4 days) or placebo. Random assignment was done with a web-based system and was stratified according to the participating centre and the duration of invasive mechanical ventilation before inclusion in the trial (<12 h, 12-24 h, and >24-72 h), and treatment was administered within the first 96 h of invasive mechanical ventilation. To minimise the risk of adverse events, the IVIG administration was divided into four perfusions of 0·5 g/kg each administered over at least 8 hours. Patients in the placebo group received an equivalent volume of sodium chloride 0·9% (10 mL/kg) over the same period. The primary outcome was the number of ventilation-free days by day 28, assessed according to the intention-to-treat principle. This trial was registered on ClinicalTrials.gov, NCT04350580.
FINDINGS: Between April 3, and October 20, 2020, 146 patients (43 [29%] women) were eligible for inclusion and randomly assigned: 69 (47%) patients to the IVIG group and 77 (53%) to the placebo group. The intention-to-treat analysis showed no statistical difference in the median number of ventilation-free days at day 28 between the IVIG group (0·0 [IQR 0·0-8·0]) and the placebo group (0·0 [0·0-6·0]; difference estimate 0·0 [0·0-0·0]; p=0·21). Serious adverse events were more frequent in the IVIG group (78 events in 22 [32%] patients) than in the placebo group (47 events in 15 [20%] patients; p=0·089).
INTERPRETATION: In patients with COVID-19 who received invasive mechanical ventilation for moderate-to-severe ARDS, IVIG did not improve clinical outcomes at day 28 and tended to be associated with an increased frequency of serious adverse events, although not significant. The effect of IVIGs on earlier disease stages of COVID-19 should be assessed in future trials.
FUNDING: Programme Hospitalier de Recherche Clinique.
参考来源
- Mazeraud A, Jamme M, Mancusi RL, et al. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021. PMID: 34774185. doi:10.1016/S2213-2600(21)00440-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。